Emerging as one of Canada’s top psychedelic regulatory communicators, Michael has provided insight and direction to some of the most prominent psychedelic companies and associations across the world. From stakeholder relations, public engagement and coalition building to regulatory strategies built on relationship integration, Michael thrives on working with psychedelic innovators looking to change the world.
Driven by his desire to support change in Canada’s mental health regime, Kydder Group Inc. was founded in 2018. His vision was to create a more collaborative and flexible government relations approach to solving some of the biggest regulatory challenges facing the psychedelic industry.
Michael is currently spearheading Canada’s first Memorandum of Regulatory Approval to amend current Health Canada regulations, hopefully resulting in controlled legal access to psilocybin therapy for palliative and end-of-life Canadians. He is also leading a national coalition with Field Trip Health Ltd. and Dr. Erika Dyck focused on Medical Assistance in Dying (MAID) and psychedelic therapy as a dignified, quality-of-life option for Canadians at end-of-life.